Disability standardised mean difference (lower is better) (during · children or adults with Types I or II HAE
1 finding from 1 review
Adverse events(during · children or adults with Types I or II HAE
Lanadelumab showed no clear difference in adverse events(during compared with placebo or active control (low certainty).
1 finding from 1 review
Quality of lifeAngioedema Quality of Life scale (lower score is better)(during · children or adults with Types I or II HAE
1 finding from 1 review
Disability (any validated scale) (during · children or adults with Types I or II HAE
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (during · children or adults with Types I or II HAE
Avoralstat showed no clear difference in adverse events (during compared with placebo (low certainty).
1 finding from 1 review
Risk of HAE attacks (during · children or adults with Types I or II HAE
Berotralstat showed no clear difference in risk of HAE attacks (during compared with placebo or active control (low certainty).
1 finding from 1 review
Change in number of HAE attacks (per week) · children or adults with Types I or II HAE
1 finding from 1 review
Total mortality · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Serious adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Phentermine/topiramate showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
All adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Phentermine/topiramate may leads to higher all adverse events compared with placebo (low certainty).
1 finding from 1 review
Change in systolic blood pressure as compared to placebo [mm Hg] from baseline to end of study · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Change in diastolic blood pressure as compared to placebo [mm Hg] from baseline to end of study · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Change in body weight as compared to placebo (%) from baseline to end of study · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Total mortality · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Naltrexone/bupropion showed no clear difference in total mortality compared with placebo (moderate certainty).
1 finding from 1 review
Cardiovascular morbidity · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Naltrexone/bupropion showed no clear difference in cardiovascular morbidity compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Naltrexone/bupropion showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
All adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Naltrexone/bupropion probably leads to higher all adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Change in systolic blood pressure as compared to placebo [mm Hg] from baseline to end of study · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Cardiovascular morbidity · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review
Change in diastolic blood pressure as compared to placebo [mm Hg] from baseline to end of study · Men and non‐pregnant women ≥ 18 years old with essential hypertension
1 finding from 1 review